Announcement on the Addition and Activation of the Company Name “Wuxi Hycells Biotechnology Co., Ltd.”
Release Date:
2026-02-10 16:51
Notice on Adjusting the Entity Responsible for Business Acceptance and Activating the New Issuing Entity
To All Partners, Customers, and Relevant Organizations:
To align with the company’s overall strategic development plan, further optimize resource allocation efficiency, and enhance the quality of integrated services and core competitiveness, we hereby issue the following official notice regarding the unified adjustment of the entity responsible for business undertaking and the entity authorized to issue external official documents:
Wuxi Hycells Biotechnology Co., Ltd. is the wholly owned parent company of Shanghai Hycells Biotechnology Co., Ltd.
It will be comprehensively upgraded into the operations, production, and business hub of the Hycells Bio-system, centrally handling external procurement of products, technical services, project collaborations, and various other business partnerships. Following the restructuring, the two companies will collaborate on undertaking and jointly executing relevant business activities while assuming corresponding responsibilities.
This restructuring represents an internal optimization and consolidation of the company’s organizational structure. Wuxi Hycells Biotechnology Co., Ltd. will, in accordance with applicable laws and regulations, fully succeed to all rights, obligations, and legal liabilities of Shanghai Hycells Biotechnology Co., Ltd. within the aforementioned scope of business. All previously executed contracts, agreements, and various commitments shall remain legally valid and enforceable, and we will make every effort to ensure seamless transition and smooth performance of all ongoing collaborations. The company’s core operating team, technical implementation standards, product quality control system, and service philosophy of “customer first, professional and efficient” will all remain unchanged.
This organizational restructuring will enable us to allocate resources more efficiently, focus on our core business, and deliver higher-quality, more comprehensive support and services to our partners and customers. We sincerely apologize for any inconvenience the transition may cause and express our heartfelt gratitude for your understanding, trust, and continued support.
Related News
HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)
Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.
HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)
The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.
This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board